IC
ALGS icon

Ikarian Capital’s Aligos Therapeutics ALGS Stock Holding History

Ikarian Capital’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-64,300
Closed -$2.56M – 164
2024
Q4 		$2.56M Buy
+64,300
New +$1.24M 0.35% 70

Other funds holding ALGS

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ikarian Capital's ALGS Position: Q1 2025 in Review

Ikarian Capital sold out of Aligos Therapeutics (ALGS) in Q1 2025, closing a stake of 64,300 shares — an estimated $2.56M sold.

Ikarian Capital first reported a position in ALGS in Q4 2024 and held it in 1 quarter. The position peaked at $2.56M in Q4 2024. 35 funds tracked by Wall St. Rank hold ALGS as of Q1 2025.

  • Ikarian Capital reported no remaining Aligos Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Ikarian Capital sold 64,300 Aligos Therapeutics shares in Q1 2025, an estimated $2.56M.
  • Ikarian Capital first reported a position in Aligos Therapeutics in Q4 2024 and held it in 1 quarter.
  • Ikarian Capital's Aligos Therapeutics position peaked at $2.56M in Q4 2024.
  • 35 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q1 2025.

Based on Ikarian Capital's 13F filing for Q1 2025, filed 15 May 2025.